When the American Society of Clinical Oncology (ASCO) wrapped up its 2026 annual meeting in Chicago on June 2, one breakthrough therapy made headlines around the globe: ivonescimab, an experimental lung cancer treatment developed by Chinese biopharmaceutical firm Akeso, delivered promising late-stage trial results that experts say highlight China’s rapidly expanding footprint in global drug development — and make the case for international partnership over ideological division.